Variable expressivity
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Urinary Incontinence
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Spastic tetraparesis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Spastic Quadriplegia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Spastic Ataxia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Seizures
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Rheumatoid Arthritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In RA, plasma S100A4 correlated with increased CSF2, and increased PRDM8 transcription in RA monocytes was associated with increased plasma CCL5 and IL-6, as well as therapy-resistance.
|
31037071 |
2019 |
Psychotic Disorders
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Progressive cerebellar ataxia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Primary malignant neoplasm
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Genes with DMRs were involved in inflammatory response (IRAK4 and ESM1), cancer (BRCA1 and LASP1), endocrine function (CNPY1), and male fertility (IFT140, TESC, and PRDM8).
|
28556291 |
2017 |
Paranoia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Conclusion: PRDM8 as a functional tumor suppressor is frequently down-regulated in HCC.
|
29572888 |
2018 |
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Array-comparative genomic hybridisation and targeted next-generation sequencing analysis demonstrated relative genomic stability of LyP lesions as compared with clonally related anaplastic large-cell lymphoma (ALCL) tumours, which showed 4q and 22q13 deletions involving the PRDM8 and TIMP3 tumour suppressor genes, respectively.
|
30393995 |
2019 |
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
An in vivo tumor model confirmed the antitumor role of PRDM8 in HCC growth and metastasis.
|
29572888 |
2018 |
Myoclonus
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Myoclonic Epilepsies, Progressive
|
0.300 |
Biomarker
|
disease |
CTD_human |
|
|
|
Mutism
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Mental deterioration
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
May-White Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
|
|
|
Malignant Neoplasms
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Genes with DMRs were involved in inflammatory response (IRAK4 and ESM1), cancer (BRCA1 and LASP1), endocrine function (CNPY1), and male fertility (IFT140, TESC, and PRDM8).
|
28556291 |
2017 |
Lymphomatoid Papulosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Array-comparative genomic hybridisation and targeted next-generation sequencing analysis demonstrated relative genomic stability of LyP lesions as compared with clonally related anaplastic large-cell lymphoma (ALCL) tumours, which showed 4q and 22q13 deletions involving the PRDM8 and TIMP3 tumour suppressor genes, respectively.
|
30393995 |
2019 |
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Conclusion: PRDM8 as a functional tumor suppressor is frequently down-regulated in HCC.
|
29572888 |
2018 |
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Array-comparative genomic hybridisation and targeted next-generation sequencing analysis demonstrated relative genomic stability of LyP lesions as compared with clonally related anaplastic large-cell lymphoma (ALCL) tumours, which showed 4q and 22q13 deletions involving the PRDM8 and TIMP3 tumour suppressor genes, respectively.
|
30393995 |
2019 |
Hyperreflexia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Hepatocarcinogenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
PRDI-BF1 and RIZ homology domain containing 8 (PRDM8) is a key regulator in neural development and testis steroidogenesis; however, its role in liver carcinogenesis remains to be investigated.
|
29572888 |
2018 |